Fibromyalgia (FM) with a global incidence of 2.7%-4.7%, is a poorly understood condition of widespread pain, fatigue, multiple somatic symptoms, and associated comorbidities. 1,2 Accumulating data suggest that FM incurs a high clinical and economic burden on both patients and societies, comparable with other chronic diseases such as diabetes and hypertension. The substantial burden of this condition may be caused by several factors, such as the exhausting challenges in diagnosis and management of patients, presence of various comorbidities, low quality of life, and marked social invalidation. 3,4 Patients with FM often have a long journey to correct diagnosis and management. They undergo multiple visits, numerous investigations, and treatments, even after being diagnosed with FM, mainly because of the patient's and physician's dissatisfaction with their consultations. There is no reference standard of diagnosis or